All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

PXS-5505: Investigational New Drug application has been submitted to the FDA

Jul 23, 2020

Following the recent U.S. Food and Drug Administration (FDA) orphan drug designation, an Investigational New Drug (IND) application has been submitted for a phase I/II study of PXS-5505, a pan-lysyl oxidase (LOX) inhibitor, which is currently under development for the treatment of myelofibrosis.

PXS-5505 has been previously tested in healthy volunteers in a phase I study. The IND submission protocol covers a dose escalation study for 1 month, and an open-label, 6-month treatment phase in patients who are not receiving a Janus kinase inhibitor. The study is planned to be started by the end of 2020 and be completed in 2022.

Inhibition of LOX family members is expected to show benefits of reduced fibrotic burden and to have favorable effects on aberrant blood cell production seen in myelofibrosis.

  1. Pharmaxis submits Investigational New Drug application for treatment of myelofibrosis. Published Jul 23, 2020. Accessed Jul 23, 2020.